Australian mRNA capability recognised by US genetic medicines program

22 October 2026 Australian mRNA capability recognised by US genetic medicines program What if fully personalised genetic medicines could be manufactured close to the patients who need them within a week? An Australian research facility has been selected for a US program aiming to make personalised genetic medicines faster and more accessible. The BASE mRNA […]
The infrastructure enabling cell therapy access for Australian patients

17 September 2026 The infrastructure enabling cell therapy access for Australian patients A powerful cellular immunotherapy developed by Professor Rajiv Khanna AO and his team at QIMR Berghofer and manufactured at Q-Gen Cell Therapeutics is saving lives.  The therapy targets severe viral infections caused by common viruses such as Epstein-Barr Virus that can become life […]
New antimalarial drug candidate reaches early clinical milestone

11 September 2026 New antimalarial drug candidate reaches early clinical milestone A new antimalarial drug candidate showing encouraging early clinical results is demonstrating how Australia’s national research infrastructure is helping move promising discoveries closer to new treatments. Findings from two early clinical studies show the drug candidate is well tolerated in humans and achieves blood […]
TIA-supported facility helps drive global effort to develop new therapies for mitochondrial disease

7 August 2026 The TIA-supported National Biologics Facility will play a key role in the only non-European node of a major international collaboration developing new therapies for mitochondrial disease. New genetic medicines have the potential to transform the lives of people living with devastating mitochondrial diseases, rare genetic disorders that currently have few treatment options. […]